Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts

Ascendis Pharma reported robust Q2 2025 results, significantly exceeding analyst expectations with an EPS of -0.82 (vs. -1.27 forecast) and revenue of €158 million (vs. €142.38 million forecast), largely driven by Yorvipath revenue more than doubling to €103 million. This strong performance led to a 4.87% surge in after-hours trading. The company projects achieving quarterly cash flow positivity in 2025 and further bolstered its outlook with FDA priority review for TransCon CNP and promising interim Phase 2 results for its combination therapy in achondroplasia, underscoring a strong growth trajectory.

Analysis

Ascendis Pharma delivered a robust second quarter for 2025, significantly outperforming market expectations with both revenue and earnings. The company reported an EPS of -0.82, a 35.43% beat against a forecast of -1.27, and total revenue of €158 million, surpassing the €142.38 million forecast by 11.01%. The primary catalyst for this outperformance was the exceptional commercial launch of Yorvipath, which generated €103 million in revenue, more than doubling its Q1 contribution. The U.S. launch shows strong traction, with 3,100 unique patient prescriptions from 1,500 prescribers since inception, underpinning management's confidence in its potential to achieve multi-billion euro peak annual sales. This revenue acceleration, coupled with a decrease in R&D costs to €72 million, has positioned the company to achieve quarterly cash flow positivity in 2025, a significant inflection point. Further bolstering the outlook, the pipeline has been de-risked with the FDA granting priority review for TransCon CNP (PDUFA date: November 30, 2025) and promising interim data from a combination therapy trial in achondroplasia, signaling substantial future growth drivers beyond the current portfolio.

Key Decisions for Investors

• Investors should monitor the key commercial metrics for Yorvipath, particularly the rate of new patient enrollments and the timeline for conversion to paid therapy, as these are the primary drivers for near-term revenue acceleration and achieving guided cash flow positivity.
• The upcoming PDUFA date of November 30, 2025, for TransCon CNP is a major binary catalyst that could significantly expand the company's addressable market and solidify its growth trajectory for the coming years.
• While the top-line growth is impressive, it is prudent to track the increase in SG&A expenses, which rose to €107.6 million, to ensure disciplined cost management and the sustainability of the company's path to profitability.
• Given the stock's 40% year-to-date return and proximity to its 52-week high, investors should assess if the current $12.01 billion market capitalization fully prices in the successful launch of Yorvipath and the potential approval of TransCon CNP.